Novo Nordisk A/S (NVO.N)
23 Feb 2017
* Says the board of directors proposes election of Kasim Kutay and Helge Lund as new members of the board of directors at the annual general meeting
* Novo Nordisk, Deutsche Bank among top losers after poor results
LONDON, Feb 2 European shares fell on Thursday after disappointing company updates, with Denmark's Novo Nordisk leading the market down and Finnish retailer Kesko weakening on lower-than-expected sales.
Feb 2 Drugmaker Novo Nordisk CEO Lars Fruergaard Jorgensen made the following comments during a call with journalists:
COPENHAGEN, Feb 2 Denmark's Novo Nordisk , the world's top maker of diabetes drugs, said fourth-quarter operating profit came in a touch below forecasts and lowered its 2017 operating profit and sales growth outlook measured in local currency terms.
* Says 2017 sales growth is expected to be in the range of a decline of 1 percent to a growth of 4 percent measured in local currencies
Stock futures signal slightly higher market open. For more see the European equities LiveMarkets blog
LONDON, Jan 31 Live coverage of European markets now available on cpurl://apps.cp./cms/?pageId=livemarkets
NEW YORK, Jan 30 Three of the biggest makers of diabetes treatments, Sanofi SA, Novo Nordisk and Eli Lilly & Co, were named in a class action lawsuit about price fixing filed by a group of patients.
* Says enters collaboration with University of Oxford on type 2 diabetes and invests 115 million pounds ($144.52 million)in new research centre
LONDON, Jan 30 Novo Nordisk, the world's top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research centre in Britain, undeterred by Brexit.